The 2018 Annual General Meeting of Orion was held on Tuesday, 20 March 2018 in Helsinki.
18 July 2018 I Half-Year Financial Report 1-6/2018 and related materials are published. View CEO's webcast presentation or have a look at Orion's latest investor slide set.
The Closing of the transaction took place on 30 April 2018.
26 Feb 2018 I Orion's Financial Statement documents for 2017 are published, and include Financial Statements, the report of the Board of Directors and the Auditor's report.
|7/18/2018||Orion Group Half-Year Financial Report January-June 2018|
|7/18/2018||Orion Corporation's financial reporting and Annual General Meeting in 2019|
|4/24/2018||Orion Group Interim Report January-March 2018|
|4/21/2018||Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook|
|7/6/2018||Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun|
|7/5/2018||Publishing of Orion Corporation's Half-Year Financial Report for January-June 2018 on 18 July 2018|
|6/14/2018||Fermion's new plant operational in Hanko - nearly 100% of production is exported|
|6/13/2018||Orion to join John Nurminen Foundation's Clean Baltic Sea projects as a new main partner|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.